



PRIOR AUTHORIZATION REQUEST FORM

Regorafenib (Stivarga®) / Hepatocellular carcinoma

DECLARATION OF THE INSURED PERSON

Section 1: Information about the participant and the patient			
Name of Participant	Insurance Policy / Certificate	Name of Employer	
Name of Patient	Date of Birth (YYYY/MM/DD)	Telephone	
Address (house number and street name)	City/Town	Province	Postal Code

Section 2: Other prescription drug insurance			
Do you have other prescription drug insurance?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
If so, please answer the following:			
What type of plan is it?	<input type="checkbox"/> Private	<input type="checkbox"/> Public	
Have you ever submitted a claim for this drug to the other insurer?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
What is the status of the claim?	<input type="checkbox"/> Accepted	<input type="checkbox"/> Refused	<input type="checkbox"/> Under review
Did this insurer ask you to complete a prior authorization request?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
If so, what is the status of the prior authorization request?	<input type="checkbox"/> Accepted	<input type="checkbox"/> Refused	<input type="checkbox"/> Under review
Please enclose acceptance or refusal documents, if applicable			

Section 3: Authorization to disclose personal information	
I certify that the information in this prior authorization request is complete, accurate and true.	
I authorize physicians and other health care professionals, medical, paramedical or clinical institutions, care coordinators, members of SSQ's Preferred Pharmacy Network (outside Quebec only) and any public or parapublic organization, including Régie de l'assurance maladie du Québec, to disclose to SSQ, Life Insurance Company Inc. (SSQ) any of my personal information including and without limitation, any medical information and medical evaluations in connection with the processing of this request. I hereby waive their confidentiality obligation and authorize them to disclose the requested information to SSQ. In addition, I authorize SSQ to disclose to the previously named third parties any of my personal information including and without limitation any medical information and medical evaluations in connection with the processing of this request.	
Photocopies of this document have the same value as the original.	
Signature of patient (parent/legal guardian) _____	Date _____

IMPORTANT:
All correspondence concerning this form will be sent to the address indicated in the participant's file.

Send us this duly completed form by mail or by fax at: 1-855-453-3942.
Telephone: 418-651-2588/1-800-380-2588 – Fax: 1-855-453-3942 Address: 2525 Laurier Blvd, P.O. Box 10500, Quebec City, QC G1V 4H6



PRIOR AUTHORIZATION REQUEST FORM

Regorafenib (Stivarga®) / Hepatocellular carcinoma

DECLARATION OF THE PHYSICIAN

Section 4: Information about the prescribing physician		
Name of Physician	Specialty	Licence No.:
Telephone	Fax	
I hereby certify that the information in this request is accurate:		
Signature of Physician _____		Date _____

Section 5: Drug covered by the authorization			
Drug name Regorafenib	Pharmaceutical form	Strength	Dosage Dose: _____ Frequency of administration: _____
Type of request	<input type="checkbox"/> First request Complete Section 6		<input type="checkbox"/> Continuation of treatment Complete Section 7 Also complete Section 6 if this is the first authorization requested from SSQ



Section 6: Clinical information (first request)

Therapeutic Indication

Hepatocellular carcinoma resistant to sorafenib

Other. Specify: _____

About sorafenib

The patient tolerated a previous sorafenib treatment, defined by the administration of a dose equal to 400 mg or more per day for less than 20 of the 28 days before ceasing sorafenib

Other. Specify: _____

Hepatic damage stage

Child-Pugh A B C Other. Specify: _____

Value of the ACTUAL performance status

ECOG 0 1 2 3 4

Administration of regorafenib

In monotherapy

Other. Specify: _____

Section 7: Clinical information (Continuation of treatment)

Observed beneficial clinical effect

Start date of treatment: _____

Absence of disease progression

Other. Specify: _____

Confirmation by imaging

Response to treatment confirmed by imaging

- Date of last imaging: _____

Response to treatment NOT confirmed by imaging

- Date of next imaging: _____
- Reason that prevented proceeding with imaging: _____



PRIOR AUTHORIZATION REQUEST FORM

Regorafenib (Stivarga[®]) / Hepatocellular carcinoma

Section 8: Additional information
